SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

FDA approval provides an important option for those unable to take oral formulation of TPOXX

Shares are moving higher today by 30% in the pre-market on FDA approval of IV TPOXX  for the treatment of small pox.

Shares are trading around $9.50 as I’m wiring this on more than 15,000 trades and 2.3 million plus shares and climbing.

https://www.globenewswire.com/news-release/2022/05/19/2446804/9738/en/SIGA-Receives-Approval-from-the-FDA-for-Intravenous-IV-Formulation-of-TPOXX-tecovirimat.html